The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

95

Portfolio companies

58

M&A and IPOs

26

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2017 (NASDAQ: ANAB)
IPO in 2018; Acquired by Eli Lilly in 2018
IPO in 2018 (NASDAQ: GRTS)
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
Acquired by AbbVie in 2019
Merger with Scilex Pharmaceuticals in 2019

Life Sciences News

Mavupharma

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Phathom Pharmaceuticals

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

Semnur Pharmaceuticals

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Passage Bio

Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases

View All News